Serum teriflunomide concentrations in routine multiple sclerosis therapy: A cross-sectional pilot study

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F24%3AE0110804" target="_blank" >RIV/00843989:_____/24:E0110804 - isvavai.cz</a>

Alternative codes found

RIV/61988987:17110/24:A2502NEY

Result on the web

<a href="https://www.sciencedirect.com/science/article/pii/S0022510X24000455?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S0022510X24000455?via%3Dihub</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.jns.2024.122910" target="_blank" >10.1016/j.jns.2024.122910</a>

Result language

angličtina

Original language name

Serum teriflunomide concentrations in routine multiple sclerosis therapy: A cross-sectional pilot study

Original language description

Background: Teriflunomide is administered orally to treat relapsing-remitting multiple sclerosis. In this prospective pilot study, the free and total serum concentrations of teriflunomide obtained during routine health care were measured and their relationship with disease activity was evaluated. Methods: Eighty-nine patients were included in this study. Blood samples were collected from April 2021 to February 2022, and free and total teriflunomide serum concentrations were measured. Patient assessment involved monitoring of blood counts and potential adverse effects of teriflunomide. Results: In the steady-state group, total teriflunomide concentrations ranged from 14.7 to 144.2 mg/L, while free concentrations from 31.1 to 389.7 µg/L. In the non-steady-state group, the total concentration ranged from 2.2 to 59.3 mg/L, with free concentrations ranging from 6.8 to 143.5 µg/L. In the steady-state group, a significant inverse correlation was found between absolute peripheral blood lymphocyte count and both total and free teriflunomide serum concentrations. Conclusion: Although all patients were treated with the same dose, up to a 10-fold difference in total and free teriflunomide serum concentrations, and up to a 5-fold difference in steady-state trough concentrations were observed. This vast interindividual variability can potentially lead to toxicity or, conversely, to suboptimal therapeutic concentrations of teriflunomide, with the risk of further worsening of multiple sclerosis compensation.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30210 - Clinical neurology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2024

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Journal of the neurological sciences

ISSN

0022-510X

e-ISSN

1878-5883

Volume of the periodical

458

Issue of the periodical within the volume

article 122910

Country of publishing house

NL - THE KINGDOM OF THE NETHERLANDS

Number of pages

6

Pages from-to

1-6

UT code for WoS article

001178203200001

EID of the result in the Scopus database

2-s2.0-85184015365